Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

114 comunicati stampa

Guarda tutti i comunicati
29/07/2026
Farmaceutica
Management/Organizzazione Aziendale
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/07/2026
Farmaceutica
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
07/07/2026
Farmaceutica
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Annunci Economici
Teva Releases Q2 2026 Aide Memoire
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmaceutica
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmaceutica
Medicina Salute Benessere
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/06/2026
Farmaceutica
Medicina Salute Benessere
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0